Sino Biopharmaceutical Limited announced that "Edaravone Injection" (Brand name: Fenghaiyi (Approved specification: 20ml: 30mg), a brain neuroprotective agent developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People's Republic of China. The product was filed as a Chemicals Category 3 drug, and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. Edaravone is a free radical scavenger, which can reduce brain oedema and tissue damage, and effectively protect brain nerves. It can be used not only in the treatment of acute cerebral infarction and cerebral embolism with bleeding tendency, but also in the treatment of the rare disease amyotrophic lateral sclerosis. Edaravone is the only clinically proven effective brain neuroprotective agent to date. With clear mechanism of action, significant clinical efficacy and few adverse effects, it has become the first-line drug for acute stroke treatment in China, and is recommended by authoritative guidelines such as the "Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke in China (2018)", "Guidelines for Cerebral Hemorrhage Treatment in China (2019)" and "Guidelines for the Treatment of Rare Diseases in China (2019)". Edaravone is now widely used in neurology, neurosurgery, cardiology and emergency departments and has a large market.